What is the recommended treatment for Erdheim‑Chester disease, including targeted therapy based on BRAF V600E or other MAPK‑pathway mutations?

Treatment for Erdheim-Chester Disease

For patients with BRAF-V600E-positive Erdheim-Chester disease who have cardiac or neurologic involvement, BRAF inhibitor therapy with vemurafenib or dabrafenib should be initiated immediately as first-line treatment. 1

Treatment Algorithm Based on BRAF Mutational Status

BRAF-V600E Positive Disease

With cardiac/neurologic disease or end-organ dysfunction:

• Start BRAF inhibitor immediately (vemurafenib 480 mg twice daily or dabrafenib 50-75 mg twice daily) 1
• Vemurafenib achieves nearly 100% metabolic response rates and can reverse critical illness 1
• Start at lower doses than standard oncologic dosing due to toxicity: vemurafenib 480 mg (not 960 mg) twice daily is the recommended initial dose 1
• Consider combination BRAF + MEK inhibitor (dabrafenib + trametinib) for CNS involvement or suboptimal response 1

Without end-organ dysfunction:

• Either BRAF inhibitor OR conventional therapy (interferon-alpha/pegylated interferon-alpha) may be considered based on toxicity profile and drug availability 1
• For low-burden disease involving only bones and retroperitoneum, anakinra (100 mg subcutaneously daily) is appropriate first-line therapy 1

BRAF-V600E Negative Disease

With cardiac/neurologic disease or end-organ dysfunction:

• Empiric MEK inhibitor therapy should be strongly considered as first-line even without identified MAPK pathway mutation 1
• Cobimetinib (20-60 mg daily for 21 of 28 days) or trametinib (1-2 mg daily) 1
• MEK inhibitors show 89% overall response rate by FDG-PET-CT regardless of specific MAPK mutation 1
• Pursue next-generation sequencing to identify other MAPK-ERK pathway alterations (ARAF, KRAS, MAP2K1, NRAS) that can guide MEK inhibitor selection 1

Without access to targeted therapies or high-burden disease:

• Pegylated interferon-alpha (135-180 mg subcutaneously weekly for high-dose) or interferon-alpha (6-9 million IU subcutaneously three times weekly for high-dose) 1
• Cladribine (5 mg/m² IV daily for 5 days every 4 weeks) - most effective cytostatic agent but <50% response rate 1, 2
• Requires prophylaxis against Pneumocystis jirovecii and viruses during treatment 1

Critical Monitoring and Management Points

Pre-treatment evaluation:

• Confirm BRAF-V600E status using >1 genotyping modality (immunohistochemistry alone is insufficient) 1
• Baseline dermatology examination and electrocardiogram before BRAF inhibitors 1
• Baseline echocardiogram and ophthalmologic examination before MEK inhibitors 1

Response monitoring:

• Full-body (vertex-to-toes) FDG-PET-CT every 2-6 months initially 1
• Once best response established on 2 scans, can extend to every 6 months 1
• Annual endocrine evaluation (endocrinopathies persist despite treatment) 1

Duration of therapy:

• Continue treatment indefinitely if tolerated - 75% of patients relapse within 6 months after stopping BRAF inhibitors 1
• Maintenance with low-dose therapy in metabolic remission may be considered 1
• Attempting dose reduction or cessation only reasonable for prolonged stable minimal disease on case-by-case basis 1

Common Pitfalls and Toxicity Management

BRAF inhibitor toxicities:

• Cutaneous complications (rash, squamous cell carcinoma) - requires semiannual dermatology examination 1
• QTc prolongation - monitor ECG every 3 months 1
• Arthralgia, fatigue 1
• Paradoxical secondary neoplasia from RAS activation in BRAF-wild-type cells 1
• Rare: sarcoidosis, pancreatitis 1

MEK inhibitor toxicities:

• Serous retinopathy (reversible) - ophthalmologic exam 2-3 weeks after initiation, then every 3-4 months first year 1
• Cardiomyopathy - echocardiogram every 3 months 1
• Rash, rarely rhabdomyolysis 1

Therapies NOT recommended as monotherapy:

• Systemic corticosteroids (only for acute symptom relief like orbital edema with vision loss) 1
• Surgery (not curative due to multifocal nature) 1
• Radiation therapy (ECD is not radiosensitive) 1

Special Considerations

Most ECD patients require treatment except select cases of asymptomatic minimal burden disease that can be monitored closely 1. The discovery of MAPK pathway mutations has transformed ECD from a disease with poor prognosis to one with excellent response rates when appropriately targeted therapy is used 1.